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http://dx.doi.org/10.1016/j.jfma.201Onecornerstone of chronic kidney disease (CKD) is fibrosis, as kidneys are susceptible due to their
high vascularity and predisposition to ischemia. Presently, only therapies targeting the angioten-
sin receptor are used in clinical practice to retard theprogression of CKD. Thus, there is a pressing
need for new therapies designed to treat the damaged kidney. Several independent laboratories
have identifiedanumberofmicroRNAs that are dysregulated inhumanandanimalmodels of CKD.
This review will explore the evidence suggesting that by blocking the activity of such dysregu-
lated microRNAs, new therapeutics could be developed to treat the progression of CKD.
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2.12.011Introduction
Chronic kidneydisease (CKD) is a growingepidemicacross the
globe, but its effects are especially noticed throughout
industrialized nations. In the USA alone, CKD affects
approximately 26 million peopleda total of more than 8% of
the population.1 Furthermore, the prevalence of CKD
amongst adults in Beijing, China is about 13%,2 and about 20%& Formosan Medical Association. All rights reserved.
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3e5 CKD.3 One of the cornerstones of CKD is fibrosis, as the
kidneys are particularly susceptible due to their high vascu-
larity and predisposition to ischemia.4 CKD itself is defined as
a decrease in the glomerular filtration rate, and signs of
chronic kidney damage include the leakage of various plasma
proteins into the urine. Pathologically, CKD is characterized
by fibrosis of the glomeruli (glomerulosclerosis), interstitial
fibrosis, injury with flattening (atrophy), loss of tubule epi-
thelium, inflammation due to leukocyte recruitment, and
loss of peritubular capillaries (Fig. 1).5 Recent studies indi-
cate that myofibroblasts, the main cells responsible for fib-
rosis deposition in the kidney,may play a crucial role inmany
of the features of CKD, such as inflammation, loss of capil-
laries, and fibrosis.6 Myofibroblasts therefore represent
a new therapeutic target against CKD.
Numerous diseases and conditions may affect renal
function, leading to CKD, including diabetes mellitus, hy-
pertension, and cancer. Recipients of heart, liver, and lung
transplants are also predisposed to developing progressive
CKD, and many drugs that are used to treat life-threatening
diseases are toxic to the kidney with long lasting conse-
quences. Currently, there is a large unmet need for new
therapies to counteract the progression of CKD and the
equivalent process affecting kidney transplants, known asFigure 1 Characteristics of chronic kidney disease in glomeruli a
and surrounding tubules and peritubular capillaries (PTCs) filled wi
silver methenamine combined with periodic acid-Schiff (Jones) stai
to-back tubules with cuboidal or columnar epithelium. (B) Sclerot
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peripherally (arrow) and obliteration of capillary loops. Scleroti
destruction of the basement membrane and periglomerular fibrosi
cellularity and fibrosis in the mesangium, and basement membra
cortex from diabetic nephropathy, showing injured tubules (tubule
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(D) Trichrome stained image of kidney cortex from ischemic kidney
color), which has overtaken all of the tubules. The fibrosis is cellula
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development in the kidney cortical interstitium.chronic allograft dysfunction (CAD). CKD and CAD often
follow a relentless course, which progresses toward organ
failure, even if the initiating factors have been adequately
addressed. Furthermore, episodes of acute kidney damage
that occur during a number of illnesses or as a consequence
of medical treatment have been shown to accelerate the
progression of CKD.7 Presently, only therapies targeting the
angiotensin receptor (angiotensin receptor-1 blockers or
angiotensin converting enzyme inhibitors) are used in clin-
ical practice to retard the progression of CKD or CAD. Thus,
there is a pressing need for new therapies designed to treat
and protect the damaged kidney.
Several independent laboratories have identified a num-
ber of microRNAs (miRNAs) that are dysregulated in human
CKD with fibrosis and in animal models of CKD. miRNAs are
a family of small, noncoding RNAs that control gene
expression by inhibiting the translation of their comple-
mentary “target” messenger RNAs (mRNA).8e10 They pre-
dominantly do so by facilitating the degradation of target
mRNAs and also by inhibiting protein translation of target
mRNAs (translational suppression).11 A single miRNA si-
lences a number of functionally related genes, and the
suppression of these genes gives miRNA a functional pur-
pose. Dysregulated miRNA expression has, however, been
identified in human diseases and is also readily observed innd interstitium of kidney cortex. (A) Normal human glomerulus
th erythrocytes (*placed above examples of PTCs) stained with
n which highlights collagens. Arteriole (a) is shown. Note back-
ic glomerulus showing wedge shaped sclerotic region showing
head) and rather acellular weaker pink stained material more
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s (thick arrow). At the lower pole, a combination of increased
ne thickening in glomerular loops. (C) Jones stained image of
atrophy and tubule cell vacuolization, apoptotic cells, arrow),
les of PTCs), expansion of the interstitial space with fibrotic
ote also thickening of the tubule basement membrane (black).
disease showing marked expansion of interstitial fibrosis (cyan
r showing inflammatory cells and myofibroblasts. The remaining
hema showing cellular mechanisms of chronic kidney disease
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NAs can attenuate the manifestation of disease, suggesting
that aberrant miRNA can contribute to disease patho-
genesis.13,14 We will therefore explore the evidence sug-
gesting that by blocking the activity of one or more of such
dysregulated miRNA, new therapeutics could be developed
to treat the progression of CKD and CAD.15The role of fibrosis and epithelial cell injury in
kidney disease
Recent studies, primarily from animal models of kidney
disease, have identified a separate lineage of cells of
mesenchymal origin in the normal kidney referred to as
“pericytes” or “resident fibroblasts”. These cells represent
>5% of normal kidney cells and perform critical homeo-
static and regenerative functions, particularly with respect
to microvascular homeostasis.16e18 In CKD, these pericytes
and resident fibroblasts become activated and are then
referred to as myofibroblasts (Fig. 1). Myofibroblasts are
the contractile cells that deposit fibrillar pathological ma-
trix, known as fibrosis or scar tissue, in the kidney. Nor-
mally, pericytes nurse capillaries and support microvascular
stability; however, when they become myofibroblasts, they
no longer perform these functions. Activated pericytes (i.e.
myofibroblasts) leave capillaries unstable and prone to
ineffective angiogenesis, increasing their permeability and
often leading to capillary demise, which is seen in the
kidney as capillary rarefaction.19
Myofibroblasts in the glomerulus deposit fibrillar patho-
logical matrix known as mesangial matrix expansion or
mesangial nodules, and this is referred to as glomerulo-
sclerosis when combined with loss of glomerular capil-
laries.19 Pathological fibrillar matrix (fibrosis) also
accumulates in the virtual space between capillaries and
tubules of the nephron or around capillaries of the glomer-
ulus, thereby destroying local structures (Fig. 1). In the glo-
merulus, fibrosis frequently accumulates initially in the
mesangial area, along the capillary loop itself, or amongst
proliferating cells that occupy the urinary space, often
known as a “crescent”. The fibrotic material formed
throughout these regions of the kidney encroaches on cap-
illaries and prevents them from functioning. In addition,
myofibroblast are contractile and can distort tissue archi-
tecture, as these cells are also inflammatory cells secreting
innate immune cytokines, chemokines, and oxygen radicals
(Fig. 1). Overall, fibrosis reduces nephron function and pro-
motes tissue ischemia, distorting normal tissue architecture.
Myofibroblasts, which cause fibrosis, are a source of inflam-
mation and promote loss of capillaries. Myofibroblast are
a major new target for therapeutics in kidney disease.19
Numerous studies have identified cell stress or cell injury
in the tubule epithelial compartment, particularly the prox-
imal tubule, as a stimulus for fibrosis.20 Increasingly, it is
recognized that damaged or stressed epithelial cells exhibit
a number of stereotyped responses: endoplasmic reticulum
(ER) stress and the unfolded protein response; apoptosis and
necrosis; activation of epithelial to mesenchymal transition
genes; activation of transforming growth factor-b (TGFb);
and cell-cycle arrest. Proximal tubule cells are particularly
dependent on aerobic generation of high levels of ATP forsurvival and health. Therefore, factors that affect or com-
promise ATP generation have a profound impact on epithelial
cell function. Not only do injured and stressed epithelial cells
fail to perform normal functions, which are vital to the kid-
ney, but they also generate a wide array of profibrotic and
inflammatory factors that can drive the manifestations of
CKD from cell to cell signaling mechanisms (Fig. 1).
Evidence of microRNA dysregulation in kidney
disease
Although there do not appear to be kidney-specific micro-
RNAs (miRNAs or miRs), a kidney signature has been reported
by a number of recent studies usingmicroarray approaches.21
In addition, a consistent pattern of upregulated and down-
regulated miRNAs has been described in response to acute
and chronic kidney injuries.11,22 Some of these miRNA
changes will reflect recruitment of inflammatory cells, but
many changes reflect abnormal regulation of genes by
miRNA, known as dysregulation. In transplanted human kid-
neys,miRNAprofiles fromkidneybiopsies havebeen shownto
distinguish patients with acute immunological rejection of
the kidney transplant (allograft) from patients with a kidney
transplant but no organ rejection. Acute rejection can be
diagnosed with a high degree of accuracy by determining
miRNA levels. Among the miRNA that were identified and
indicative of organ rejection were 10 (let-7c, miR-10a, miR-
10b, miR-125a, miR-200a, miR-30a-3p, miR-30b, miR-30c,
miR-30e-3p, and miR-32) that were downregulated in acute
rejectionbiopsies compared tonormal allograft biopsies, and
sevenmiRNAs (miR-142e5p,miR-142e3p,miR-155,miR-223,
miR-146b, miR-146a, and miR-342) that were upregulated.23
In a diabetic nephropathy mouse model, Putta et al24
showed that reduction of miR-192 retards renal fibrosis
and improves proteinurea. Administration of modified RNA
oligonucleotides that are complementary to the miR-192
sequence resulted in miR-192 degradation and attenuated
histological evidence of glomerular expansion and renal
interstitial fibrosis, as well as conferred improvement in
renal function in the diabetic mice.24
Utilizing amousemodel of unilateral ureteral obstruction
nephropathy, Qin et al25 demonstrated that miR-29 neg-
atively regulated fibrosis by targeting the process of collagen
matrix synthesis rather than by inhibiting myofibroblast
accumulation. miR-29 is negatively regulated by TGFb when
it signals via the Smad3 dependent pathway. By using miRNA
microarrays and real-time PCR, the investigators found that
miR-29a, miR-29b, and miR-29c family members were sub-
stantially reduced in the fibrotic kidney of UUO wild-type
mice but significantly increased in Smad3/ mice in which
renal fibrosiswas reduced.Thesefindings implicatemiR-29 in
TGFb dependent fibrosis. From a therapeutic perspective,
the identification of miRNAs that are elevated in disease and
contribute to pathogenesis by silencing genes is critical for
the innovation of new therapies.25
miRNAs in the circulation and urine as markers
to identify and predict kidney disease
It has recently been shown that miRNAs are found in the
circulation in exosomes or stably bound to the assembly
240 I.G. Gomez et al.protein Argonaut. In addition to the blood stream, miRNAs
have been detected in urine and other secreted fluids in
a stable form.26e28 An increasing number of investigations
suggest that several circulating miRNAs are biomarkers for
cancer growth and organ injuries, such as cardiac ischemia.
Therefore, it is probable that miRNAs will be released into
urine or blood during kidney disease. Recently, miR-21 was
shown to be upregulated in both the medulla and cortex of
a rat model after gentamicin-induced nephrotoxicity.29 The
researchers went further to investigate urine samples from
patients with acute kidney injury in the intensive care unit
and compared those samples to healthy subjects. They
found a significant 1.2-fold increase of miR-21 in the urine
of acute kidney injury patients compared to healthy pa-
tients. Although there does not appear to be a miRNA
restricted to the kidney in disease or development, future
studies should be focused on the identification of patterns
of miRNA that are released into the urine or blood by
damaged kidneys.Figure 2 Kidney disease in mice that lack miR-21 compared
to WT mice following kidney injury. Sirius red stained low
power images showing red stained interstitial fibrosis following
kidney injury, and medium power images showing periodic
acid-Schiff stain of kidney cortex after injury. Note reduced
fibrosis in kidneys lacking miR-21. Also note that kidney epi-
thelial cells are more injured in WT showing increased flat-
tening and loss of typical purple brush border, whereas these
features are more preserved in miR21/ kidneys.miRNA-21 in kidney disease
Transgenically over-expressed miRNA-21 in lymphocytes
appears to function as an oncogenic miRNA (i.e. an onco-
mir).13 In these lymphocytic cancer cells, miR-21 prevents
apoptotic cell death; however, miR-21 is not specific to
cancer cells as it is widely expressed in many tissues,
including the normal kidney. Conversely, upregulation of
miR-21 has been indicated in a range of kidney diseases,
and is one of the most highly expressed miRNAs in kidney
disease.11 Recent studies reported that miR-21 levels were
increased in cardiac fibroblasts of failing hearts and it was
shown that miR-21 results in over-activation of the P42/P44
mitogen activated protein (MAP) kinase signaling pathway
in cardiac fibroblasts, but not in cardiomyocytes.10 Silenc-
ing of miR-21 by a specific modified RNA oligonucleotide
complementary to the miR-21 sequence, which was con-
jugated to cholesterol and known as “antagomir”, reduced
cardiac P42/P44 MAP kinase activity and interstitial fibrosis
and attenuated cardiac dysfunction in models of cardiac
failure in mice. Although follow-up studies failed to repli-
cate these findings,30 these cardiac studies suggested that
miR-21 may play a role in amplifying the fibrogenic process
and is therefore a potential target in other organs, such as
the kidney.9
Chau et al produced a mouse where the locus for miR-21
was successfully mutated.11 These mice were normal at age
8 months in a sterile animal housing facility, exhibited
normal fertility, and the kidneys developed normally.
However, in several models of CKD, the miR21/ kidneys
suffered less tubule injury/atrophy, less fibrosis, less
capillary destruction, and reduced P42/P44 MAP kinase
pathway activation in response to the same degree of injury
(Fig. 2).11 The investigators developed and synthesized
modified oligonucleotides based around ribose nucleotides
that are complementary to miR-21. These freely enter cells
in the kidney when injected subcutaneously, bind to
intracellular miR-21 and stimulate its degradation, effec-
tively silencing miR-21.11 Administration of these oligonu-
cleotides (anti-miR-21) to mice recapitulated the results of
miR21/ in kidney disease, and additionally reversedkidney disease. In a microarray analysis of the miR21/
mouse kidneys, it was found that in nondiseased kidneys,
there were no genes that were normally silenced by miR-
21, even though it is expressed at quite high levels. How-
ever, in response to kidney injury, a characteristic pattern
of genes, with the complementary sequence in their 3’UTRs
to miR-21, were silenced in the miR21þ/þ kidneys com-
pared to the miR21/ kidneys.11 These observations sug-
gested that, unlike many other miRNAs, miR-21 is
sequestered in an intracellular compartment and released
into the cytoplasm in response to cell stress where it be-
comes active. The genes (>80) that were silenced in dis-
eased kidneys by miR-21 were surprising. Rather than
inflammatory, innate immunity, or fibrotic/matrix turnover
genes, the genes were all involved in cell metabolic func-
tions. In particular, there were genes that play crucial roles
in lipid metabolism, fatty acid oxidation, and redox regu-
lation in the mitochondria.11
The peroxisomal and mitochondrial fatty acid oxidation
metabolic pathway, regulated by the transcription factor
peroxisome proliferator activated receptor-a (PPARa), was
identified as a major target for miR-21; in fact 9 distinct
enzymes induced by PPARa in this catalytic pathway were
all specifically silenced by miR-21 in the kidney (Fig. 3).11
miR-21 engaged this pathway in kidney epithelial cells,
particularly proximal tubules, but also in myofibroblasts.
Furthermore, over-expression of PPARa protected kidneys
from the development of fibrosis. Finally, it was shown that
while Ppara/ mice exhibited increased fibrogenesis and
epithelial injury, oligonucleotides that block miR-21 action
were no longer able to inhibit epithelial injury and fibro-
genesis, implicating the PPARa pathway as a major target
of miR-21 in kidney disease.11 Previously, PPARa was
Figure 3 Schema showing important gene products and pathways silenced by miR-21 in animal models of kidney disease. miR-21
silences the transcriptional regulator PPARa and many of the downstream enzymes in fatty acid metabolism that are also regulated
by PPARa, including transporters and enzymes (shown in grey) of the b-oxidation metabolic pathway of fatty acids that occurs in
peroxisomes and mitochondria. The consequence of miR-21 activity is to reduce metabolism of fatty acids. In addition, miR-21
increases reactive oxygen species and toxin formation/accumulation. First, by suppressing peroxisome formation and activity,
the metabolism of H2O2 is retarded by miR-21, and second, miR-21 silences genes that inhibit reactive oxygen species generation in
mitochondria, including MPV17-like which exerts its inhibitory function by binding to the mitochondrial protease HrtA2. In this
configuration HrtA2 is also anti-apoptotic.
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kidney injury.31,32 PPARa stimulates the proliferation of
peroxisomes, and these organelles play a critical role in the
oxidation of fatty acids, also providing detoxification and
metabolism of oxygen radicals, including H2O2. Detox-
ification of accumulated fatty acids in injured cells and
metabolism of excess oxygen radicals are important factors
that promote cell survival and function. In addition, per-
oxisomes are a major site of long chain fatty acid metab-
olism by the a- and b-oxidation pathways. Epithelial cells
rely heavily on fatty acids for ATP generation. While per-
oxisomal b-oxidation enzymes reduce very long chain fatty
acids, mitochondrial b-oxidation enzymes oxidize fatty
acids with less than 22 carbon atoms, resulting in ATP
generation.31 In proximal tubules, nuclear receptor PPARa
plays a pivotal role in regulating peroxisomal and mito-
chondrial fatty acid oxidation in kidney tissue.32 Moreover,
many of the enzymes critical in this pathway (acyl-CoA
oxidase 1; acyl-CoA dehydrogenases; and carnitine palmi-
toyl transferase) are also silenced by miR-21.11
In addition to the fatty acid metabolic pathway, Chau
et al identified enzymes and co-factors involved in the
intracellular redox state and inhibition of reactive oxygen
species (ROS) generation as miR-21 targets, particularly in
epithelial cells. Consistent with miR-21 stimulating ROS
generation in kidney epithelium, they showed that in dis-
eased kidneys from miR21/ mice there was reduced ev-
idence of ROS generation, in interstitial as well as epithelialcells.11 One of the proteins silenced by miR-21 was Mpv17-
like (Fig. 3). This obscurely-named protein was identified in
kidney epithelial cell mitochondrial membranes and has
recently been reported to interact via its PDZ domain
with a serine protease enzyme, HTRA2, which prevents
mitochondrial ROS generation and prevents mitochondrial
triggered apoptosis.33 Therefore, it is feasible that miR-21
also stimulates ROS generation in epithelial cells in
response to cell stress. Impaired fatty acid metabolism and
enhanced mitochondrial ROS generation in CKD develop-
ment and progression are all implicated in these studies.11
It is therefore interesting that excessive production of
ROS by mitochondria has been strongly implicated in CKD
progression in a number of independent studies and in
development of kidney abnormalities that occur with
normal aging.34,35 The gene Mpv17, an orthologue of Mpv17-
like, was identified more than 20 years ago as an epithelial
and neuronal restricted protein located in the mitochon-
drial inner membrane and implicated in metabolism of ROS.
Mice lacking Mpv17 spontaneously develop kidney disease
with glomerulosclerosis and interstitial diseases similar to
CKD. 36e38
In addition to these links between mitochondrial ROS
generation, kidney disease progression, and miR-21, the
families of PPAR transcription factors including PPARg and
PPARa have been drug targets for a number of years using
a class of agents known as glitazones as ligands for PPARg
and fibrates as ligands for PPARa.32 Glitazones have been
242 I.G. Gomez et al.used to treat diabetes mellitus by enhancing insulin sensi-
tivity, but have been documented in animals to exhibit anti-
inflammatory and anti-fibrotic effects in kidney disease.39
Moreover, PPARg has been suggested as a transcription
factor that inhibits myofibroblast activation in a number of
tissues including lung, liver and skin.40 Fibrates were used
in patients with diabetes and it was demonstrated that end
points of cardiovascular disease events and nonfatal myo-
cardial infarction were significantly reduced by fibrates.
Similarly, fenofibrates significantly reduced the micro-
vascular complications of Type 2 diabetes, including ne-
phropathy.39 These clinical studies suggest that stimulation
of peroxisome functions and fatty acid metabolism,
potentially by anti-miR-21, are desirable strategies in kid-
ney disease (Fig. 3).
Numerous investigators have identified that miR-21 is
upregulated inmodels of kidney disease. This upregulation is
also observed in humanCKD, kidney transplants and in native
kidney disease.11,21 Moreover, independent groups have
shown that inhibition of miR-21 has therapeutic benefits.22
These independent findings add weight to the significance
of miR-21 as a candidate target for kidney disease.
miRNAs as a potential therapeutic target in
kidney disease
Since miRNAs are located in cytoplasm of cells and
because they control cell functions, they are obvious can-
didates for therapy. In addition, because of sequence
complementarity, drugs can be designed to specifically
target a single miRNA, potentially avoiding conventional
small molecule drug side effects. Recent advances in the
development of oligonucleotides that can bind to mRNA and
silence the translation of those mRNA (known as RNA
silencing), heralded the development of small (22 nt) oli-
gonucleotides that are stable in the circulation, can freely
enter cells and, because of their sequence com-
plementarity, bind specifically causing their targets to be
silenced.11 Such anti-miRNA oligonucleotides are already in
clinical trials as therapeutics in cancer. The animal studies
reported by Chau et al showed that anti-miR-21 oligonu-
cleotides accumulate in the kidney and effectively block
miR-21 functions. Although miR-21 is normally expressed
widely, it appears that it is not active in healthy cells, but
becomes active only in stressed or injured cells. The fact
that miR21/ mice are healthy attests to a dormant role
for miR-21 in cell physiology. It is quite likely therefore that
anti-miR-21 oligonucleotides will only block miR-21 actions
in areas of tissue injury or inflammation.11 Finally, the
current anti-miR-21 oligonucleotides have been adminis-
tered to animals for several months without any toxicity. An
additional question that arises from these studies is what is
the functional role for miR-21 without disease, since it
appears to be detrimental only during disease. Currently,
miR-21 has no clear physiological role during disease-free
conditions.
Conclusion
Recent studies have identified dysregulated miRNA in ani-
mal models and human tissue samples of kidney disease.Evidence from knockout mice and miRNA-silencing oligo-
nucleotides in rodents indicates that miR-21 is an important
pathological factor in chronic kidney disease. The silencing
of metabolic pathways by miR-21 dictates an important
function in fatty acid metabolism and in the removal of ROS
in peroxisomes and mitochondria, both critical process for
reducing fibrosis and disease. It is thus likely that recent
advances in oligonucleotide technology will lead to a po-
tential new type of therapy that specifically targets and
degrades miRNAs.
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